Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Trial Profile

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Suspended
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Anastrozole (Primary) ; Everolimus (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Dec 2017 Planned End Date changed from 1 May 2018 to 1 May 2022.
    • 14 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2022.
    • 14 Dec 2017 Status changed from active, no longer recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top